Nivolumab/relatlimab

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma.[1] It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.[1] It is given by intravenous infusion.[1]

Nivolumab/relatlimab
Combination of
NivolumabProgrammed death receptor-1 (PD-1) blocking antibody
RelatlimabLymphocyte activation gene-3 (LAG-3) blocking antibody
Clinical data
Trade namesOpdualag
License data
Routes of
administration		Intravenous
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

The combination was approved for medical use in the United States in March 2022.[1][2]

References
  1. "Opdualag- nivolumab and relatlimab-rmbw injection". DailyMed. 18 March 2022. Retrieved 22 March 2022.
  2. "U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Retrieved 19 March 2022 – via Business Wire.

Further reading
  • Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. (January 2022). "Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma". N Engl J Med. 386 (1): 24–34. doi:10.1056/NEJMoa2109970. PMID 34986285. S2CID 245771473.
  • "Nivolumab". Drug Information Portal. U.S. National Library of Medicine.
  • "Relatlimab". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03470922 for "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047)" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.